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and Alessandra ModestiaAngiotensin II was reported to induce insulin-like growth
factor-I and endothelin-1 gene expression and peptide
release by ventricular cardiomyocytes. However, the
progression from cardiac hypertrophy to failure in humans
is characterized by a reduced myocyte expression of
insulin-like growth factor-I and endothelin-1,
notwithstanding the enhanced cardiac generation of
angiotensin II. In the present study we investigated the
functional status of the signaling pathways responsible for
angiotensin II-induced endothelin-1 and insulin-like
growth factor-I formation in human ventricular myocytes
isolated from patients with dilated (nU 19) or ischemic
(nU 14) cardiomyopathy and nonfailing donor hearts
(nU 6).
In human nonfailing ventricular myocytes, angiotensin II
(100 nmol/l) induced insulin-like growth factor-I and
endothelin-1 gene expression, and peptide release was
mediated by extracellular signal-regulated kinase
activation and inhibited by extracellular signal-regulated
kinase antagonism (PD98059, 30mmol/l), endothelin-1
formation being partially reduced also by c-Jun N-terminal
kinase inhibition (SP600125, 10mmol/l); insulin-like
growth factor-I and endothelin-1 formations were
unaffected by the inhibition of p38 mitogen-activated
protein kinase (SB203580, 10mmol/l) and Janus tyrosine
kinase 2 (AG490, 10mmol/l). In failing myocytes,
angiotensin II failed to induce insulin-like growth factor-I
and endothelin-1 formation; angiotensin II-induced
extracellular signal-regulated kinase activation was
significantly impaired (S88% vs. controls) although c-Jun
NH2-terminal kinase activation was preserved. The
impaired extracellular signal-regulated kinaseopyright © Lippincott Williams & Wilkins. Unautho
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increased myocyte levels of mitogen-activated protein
kinase phosphatases.
Therefore, the altered growth factor production in failing
myocytes is associated with a significant derangement in
intracellular signaling. J Hypertens 26:2030–2039 Q 2008
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Angiotensin (Ang) II induces endothelin-1 (ET-1), and
insulin-like growth factor-1 (IGF-I) formation in isolated
ventricular myocytes. Early growth factor formation fol-
lowing the application of mechanical stimuli is also
mediated by Ang II as suggested by the observation that
the inhibition of type I receptors for Ang II inhibited
early growth factor (ET-1 and angiotensinogen) over-
expression in stretched myocytes in vitro [1] and in
experimental models of acute cardiac overload in vivo[2,3]. However, in patients with aortic valve disease,
the progression from compensatory hypertrophy to heart
failure is characterized by reduced gene expression of
ventricular myocytes and cardiac formation of insulin-like
growth factor-1 (IGF-I) and ET-1 [4], notwithstanding
a significant increase in cardiac Ang II generation [4].
The capability of myocytes to express IGF-I and ET-1
following Ang II stimulation is finally lost in ventricular
myocytes isolated from failing explanted human hearts
[5]. These data and the absence of differences in Ang IIrized reproduction of this article is prohibited.
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Table 1 Characteristics of individuals investigated
NF (n¼6) ICM (n¼14) DCM (n¼19)
Age (years) 467 595M 5113M
Sex (M/F) 4/2 11/3 13/6
BSA (m2) 1.870.12 1.910.14 1.880.20
SAP (mmHg) 1188 11111 1159
LVEDDI (mm/m2) 263 385M 426M
LVESDI (mm/m2) 224 325M 365M
LVMI (g/m2) 10715 22136M 25060M
EF (%) 635 228M 197M
ESS (Kdyne/cm2) 709 18136M 19515M
Vcf (s1) 1.160.17 0.520.2M 0.480.17M
CI [l/(m2min)] 2.130.48 1.950.50
LVEDP (mmHg) 227 269
MPAP (mmHg) 3311 3712
BSA, body surface area; CI, cardiac index; DCM, dilated cardiomyopathy; EF,
ejection fraction; ESS, end systolic stress; ICM, ischemic cardiomyopathy;
LVEDDI, left ventricular end diastolic diameter index; LVEDP, left ventricular
end diastolic pressure; LVESDI, left ventricular end systolic diameter index; LVMI,
left ventricular mass index; MPAP, mean pulmonary arterial pressure; NF, nonfail-
ing; SAP, systolic aortic pressure; Vcf, mean midwall velocity of circumferential
fiber shortening. MP<0.05 vs. NF.type 1 (AT1) and type 2 (AT2) receptor populations
between nonfailing and failing human ventricular myo-
cytes [5] might lead to the hypothesis that the progression
to failure is characterized by an alteration of intracellular
signaling pathways. Different studies investigated
protein amounts and activity of the three branches of
the mitogen-activated protein kinase (MAPK) family,
extracellular signal-regulated kinase (ERK), c-Jun
N-terminal kinase (JNK), and p38MAPK, in whole
homogenated human failing hearts [6,7]. In isolated
human failing ventricular myocytes, the activation of
the Ang II–Janus tyrosine kinase (JAK) 2 pathway was
recently reported [8], but information regarding
the Ang II–ERK signaling is lacking. This aspect
might be relevant because ERK is known to regulate
myocyte survival [9,10] and increases the expression of
transcription factors, which recognize specific DNA
region binding in the promoter of both IGF-I [11] and
ET-1 [12] genes. IGF-I promotes myocyte formation
and attenuates myocyte death after infarction [13].
Likewise, ET-1 is required for cardiomyocyte survival
in vivo [14] and was reported to mediate the positive
inotropic effect of Ang II [15]. MAPK activity is nega-
tively regulated by dual-specificity MAPK phosphatases
(MKPs) that are expressed in the heart and are induced
by mitogen and stress stimuli [16]. Cardiac overexpres-
sion of MKP3 was recently reported to potently block
ERK, predisposing the heart to decompensation and
failure after long-term pressure overload [17].
The present study was therefore performed to investigate
the functional status of Ang II–ERK signaling and of
protein phosphatases (MKP1, MKP2, MKP3) in failing
human myocytes.
Patients and methods
Study population
Patients with heart failure due to idiopathic dilated car-
diomyopathy (DCM, n¼ 19) or ischemic cardiomyopathy
(ICM, n¼ 14) belonging to New York Heart Association
(NYHA) class III (DCM, n¼ 11 and ICM, n¼ 8) or class IV
(DCM, n¼ 8 and ICM, n¼ 6) and scheduled to undergo
cardiac transplantation were prospectively investigated. A
recent history (less than 6months) ofmyocardial infarction
and echocardiographic evidence of valve or congenital
heart disease were exclusion criteria. Diagnosis of DCM
or ICMwas based on clinical and echocardiographic exam-
ination, cardiac catheterization, and coronary angiography.
Myocardial tissue was obtained from a noninfarcted por-
tion of the left ventricular free wall during cardiac trans-
plantation. Cardiac specimens were also obtained from the
same cardiac region of six donors with no history or signs of
heart disease and whose hearts could not be transplanted
for noncardiac reasons (nonfailing hearts) (Table 1). The
study protocol complieswith the principles of theHelsinki
declaration, was approved by our institution, and all
patients gave their informedwritten consent to participateopyright © Lippincott Williams & Wilkins. Unauthin the study. Echocardiographic and hemodynamic meas-
urements were performed as previously described [4].
Myocyte isolation
All studies were performed on freshly isolated ventricular
myocytes. After explantation, the heart was placed in
cardioplegic solution and immediately transferred to
the laboratory.
Myocytes were isolated with the enzymatic digestion
method as previously described [5,8]. Briefly, a coronary
artery branch was cannulated and perfused for 10min
with a calcium-free basic buffer (blood washout) com-
posed of Jocklik modified minimal essential medium
(MEM Joklik) supplemented with glutamine (Sigma
G5763, Sigma Chemical Co., St. Louis, Missouri, USA)
(0.3 g/l), taurine (Sigma T0625) (1.25g/l), HEPES
(Sigma H3375) (2.9mmol/l), insulin (20U/l), penicillin–
streptomycin (Sigma P3539, 50U/ml and 0.05mg/ml,
respectively) 5ml/l, and CaCl2 (7.5mmol/l), pH 7.4. The
basic bufferwas previously leaked throughfilters of 0.2mm
pore size. Perfusion was then switched to collagenase
solution, composed of 0.5mg/ml of Worthington type II
collagenase (100units/ml) in basic buffer supplemented
with CaCl2 30mmol/l (20ml/min for 20–25min). The
collagenase-perfused tissue was then minced and tissue
was collected in tubes containing basic buffer supple-
mented with bovine serum albumin (0.5%), CaCl2
(0.3mmol/l), and taurine (10mmol/l). Individualmyocytes
were then released from the tissue by mechanical agita-
tion.The suspensionwas filtered through a sterile gauze to
separate cells from tissue mass. The populations of cells
were then washed using two complete cycles of low-speed
centrifugation. The dispersed cells were finally preplated
for 30min to minimize fibroblast contamination. Typical
preparations contained 60–70% rod-shaped, quiescentorized reproduction of this article is prohibited.
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cross-striations and sarcomere patterns.
Staining of sarcomeric alpha-actinin and myosin was
performed using antisarcomeric alpha-actinin mono-
clonal antibodies (mAbs) at a dilution of 1 : 800 and rabbit
polyclonal antiskeletal myosin mAbs at a dilution of
1 : 200 (both from Sigma Chemical Co.), respectively.
Samples were then washed in PBS/1% bovine serum
albumin three times for 5min each. Secondary detection
was carried out by incubation for 30min at room
temperature with a 1 : 200 dilution of fluorescein-
conjugated or rhodamine-conjugated, noncross-reactive,
goat antimouse or antirabbit antibodies, respectively.
According to their appearance under phase contrast
microscopy and by immunocytochemical staining, non-
myocyte cells were found to account for less than 2% of
the total cells [5,8].
Angiotensin II stimulation and measurement of
insulin-like growth factor-I and endothelin-1
After isolation, myocytes (105 cell/ml) were suspended
in Dulbecco’s Modified Eagle’s Medium supplemented
with penicillin G (10 000U/ml) and streptomycin
(10mg/ml) under an atmosphere of 95% air and 5%
CO2 at 378C.Myocyte levels of AT1 and AT2 transcripts
were quantified with reverse transcriptase-PCR, using
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
as internal standard [5].
To investigate the relative role of the two angiotensin
receptor subtypes, myocytes were preincubated for
30min with selective AT1 or AT2 receptor antagonists
(valsartan, 1mmol/l or PD123319, 1mmol/l, respectively).
To investigate the relative role of the different intra-
cellular pathways in the Ang II-mediated activation
of IGF-I and ET-1 gene expression and peptide
release, nonfailing myocytes were preincubated
(60min) with inhibitors of ERK (PD98059, 30mmol/l),
JNK (SP600125, 10mmol/l), p38 MAPK (SB203580,
10mmol/l) and JAK2 (AG490, 10mmol/l). Preliminary
experiments using the trypan blue exclusion method
had shown that no toxic effects were detected when
the myocytes were incubated for as long as 6 h with the
various inhibitors of intracellular signaling pathways.
Myocytes were then stimulated with Ang II (100 nmol/l)
[5,18]. At baseline and after 2 h, the conditioned media
and myocytes were separated by centrifugation and
immediately frozen in liquid nitrogen.
IGF-I and preproET (ppET)-1 mRNA expression and
peptides released in theconditionedmediaweremeasured
with reverse transcriptase-PCR and radioimmunoassay
(Peninsula Lab, SanCarlos, California, USA) as previously
described in detail [4,5].opyright © Lippincott Williams & Wilkins. UnauthoStudies of the angiotensin II intracellular signaling
pathways
After 5, 10, 20, 30, and 60min of incubation under the
conditions described above, the reaction samples
were washed in ice-cold PBS and lysed in ice-cold lysis
buffer (50mmol/l Tris-HCl, 150mmol/l NaCl, 1mmol/l
sodium orthovanadate, 100mmol/l NaF, 2mmol/l
EGTA, 1% NP40, 1mmol/l PMSF, pH 7.5) supple-
mented with Protease Inhibitor Cocktail (P8340, Sigma)
and Phosphatase Inhibitor Cocktail (P5726, Sigma).
Lysates were kept on ice and then sonicated four times
for 5 s. After centrifugation, protein concentration in the
supernatant fraction was assessed using Bradford’s
method.
Measurement of mitogen-activated protein kinase activity
Activated ERK dually phosphorylated on T202/Y204 was
immunoprecipitated from lysate-stimulated cells and
used to measure the incorporation of [g-33P]ATP into
a specific p44/42 MAPK substrate (synthetic peptide,
KRELVEPLTPAGEAPNQALLR) [19].
JNK activity was assayed using a nonradioactive method
(Cell Signaling Technology, Beverley, Massachusetts,
USA) [20]. Briefly, cell lysate (200mg of protein) was
incubated overnight at 48C with 2mg glutathione-S-
transferase (GST)–c-Jun protein beads. Complexes
were collected, washed, and resuspended in 50ml kinase
lysis buffer with 100mmol/l ATP. Samples were incu-
bated for 30min at 308C and the reaction was terminated
with sample buffer. After separation with 10% sodium
dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE), western blot was performed using anti-
phospho-c-Jun antibody.
Western blotting studies
Samples (25mg proteins) were then separated with 8%
SDS-PAGE. The gel was then transferred to nitrocellu-
lose membrane (Hybond-ECL, Amersham Biosciences,
Piscataway, New Jersey, USA) and blocked by incubation
for 1 h at room temperature in tris-buffered saline with
Tween-20 (TTBS, pH7.4) and5%skimmedmilk powder.
Membranes were then incubated overnight at 48C with
polyclonal rabbit antihuman ERK, polyclonal rabbit anti-
human phospho-ERK (Cell Signaling Technology,
Beverly, Massachusetts, USA) [21], polyclonal rabbit
antihuman MKP1 (sc-1199 Santa Cruz, Santa Cruz,
California, USA), MKP2 (sc-10797 Santa Cruz), and
MKP3 (sc-28902 Santa Cruz). The nitrocellulose mem-
branes were then washed twice for 10min with TTBS
and incubated for 30min with goat antirabbit or sheep
antimouse immunoglobulin G (IgG) (as appropriate)
horseradish peroxidase conjugate antibody (Amersham
Biosciences). After extensivewashing, thebound antibody
was visualized using a chemioluminescent detection
system.rized reproduction of this article is prohibited.
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Fig. 1
(a) Expression of glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ppET-1, and IGF-I genes by ventricular cardiomyocytes isolated from the
hearts of donors (NF, n¼4), and patients with dilated (DCM, n¼12) or ischemic cardiomyopathy (ICM, n¼9) after 2 h incubation with buffer (Buff) or
Ang II (100 nmol/l). Effects of inhibitors of ERK (PD098059, 30mmol/l), JNK (SP600125, 10mmol/l), JAK2 (AG490, 10mmol/l), and p38MAPK
(SB203580, 10mmol/l). Representative reverse transcriptase-PCR experiments. (b, c) Release of big ET-1 (b) and IGF-I (c) in the conditioned media
after 2 h stimulation with Ang II (100 nmol/l) for myocytes isolated from controls (n¼6), DCM (n¼19), and ICM (n¼14). Data were normalized using the
peptides released by unstimulated cells. Effects of ET-1 antagonist (BQ123, 10mmol/l), and inhibitors of ERK (PD098059, 30mmol/l), JNK (SP600125,
10mmol/l), JAK2 (AG490, 10mmol/l), and p38MAPK (SB203580, 10mmol/l). yP<0.05 vs. myocytes incubated with buffer (saline); P<0.05 vs. Ang
II-stimulated myocytes. (d) Expression of mRNAs for GAPDH, AT1, and AT2 receptor subtypes in ventricular myocytes isolated from donors (NF) and
failing (ICM, DCM) hearts. Left panel: representative reverse transcriptase-PCR experiments. Right graph: densitometric Ang II receptor/GAPDH (ATR/
GAPDH) mRNA ratio (empty bars, AT1; filled bars, AT2) in myocytes isolated from NF (n¼4), ICM (n¼12), and DCM (n¼9) hearts. Ang II, angiotensin
II; AT1, angiotensin II type 1; AT2, angiotensin II type 2; DCM, dilated cardiomyopathy; ERK, extracellular signal-regulated kinase; ET-1, endothelin-1;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; ICM, ischemic cardiomyopathy; IGF-I, insulin-like growth factor-1; JAK2, Janus tyrosine kinase 2;
JNK, c-Jun N-terminal kinase; MAPK, mitogen-activated protein kinase; NF, nonfailing; ppET-1, prepro endothelin-1.Statistical analysis
Data are expressed as meanSD. Autoradiograms were
analyzed using an image analyzer. Comparisons
between groups were performed using one-way analysisopyright © Lippincott Williams & Wilkins. Unauthof variance and student’s t test, followed by the
Tukey multiple-range comparison test, as appropri-
ate. A P value of 0.05 was considered statistically
significant.orized reproduction of this article is prohibited.
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Signaling pathways involved in the angiotensin
II-induced endothelin-1 and insulin-like growth
factor-I production by human nonfailing myocytes
Ang II stimulation of nonfailing myocytes enhanced
ET-1 and IGF-I gene expression (Fig. 1a) as well as
peptide release in the incubation medium (Fig. 1b and c).
The Ang II-induced increase in big ET-1 or IGF-I
formation in nonfailing myocytes was mediated by the
AT1 receptor as the response was selectively inhibited by
valsartan (Fig. 1b and c). Conversely, the release of
both big ET-1 and IGF-I was unaffected by the specific
antagonist for the type A ET-1 receptor subtype (BQ123)
(Fig. 1b and c), thus excluding an autocrine/paracrine
effect of ET-1.
The release of big ET-1 induced by Ang II (100 nmol/l)
in nonfailing myocytes was abolished by the ERK inhibi-
tor PD98059 and reduced (50%) following the JNK
inhibition (SP600125) (Fig. 1b). ERK inhibition also
blocked the formation of IGF-I in Ang II-stimulated
nonfailing myocytes (Fig. 1c). The effects of ERK
antagonism on IGF-I and ET-1 expression in control
myocytes were also confirmed at transcription levelopyright © Lippincott Williams & Wilkins. Unautho
Fig. 2
(a) ERK activation in Ang II (100 nmol/l) stimulated nonfailing (NF) myocytes
in NF myocytes and in myocytes isolated from ICM and DCM patients are
course of the ratios of phosphorylated to total ERK (p-ERK/ERK) for nonfa
Effects of AT1 (Valsartan) and AT2 (PD123319) selective antagonists on ER
failing myocytes (ICM, n¼14; DCM, n¼19). Ang II, angiotensin II; DCM, d
ischemic cardiomyopathy; NF, nonfailing; p-ERK, phosphorylated extracellu
yP<0.05 vs. NF myocytes.(Fig. 1a). Conversely, big ET-1 and IGF-I release were
unaffected by p38 MAPK and JAK2 inhibitors
(SB 203580 and AG 490, respectively) (Fig. 1b and c).
Ang II stimulation failed to enhance ET-1 and IGF-I
production in human ventricular failing myocytes both
from DCM and ICM hearts (Fig. 1) as previously demon-
strated [5]. Reverse transcriptase-PCR studies confirmed
that the altered response was not related to AT1 and AT2
changes in gene expression in isolated failing myocytes
(Fig. 1d).
Altered angiotensin II-mediated extracellular signal-
regulated kinase activation in human failing myocytes
Ang II induced a prompt phosphorylation of ERK in
nonfailing human ventricular myocytes, which signifi-
cantly increased after 5min (þ24% vs. nonstimulated
myocytes, P< 0.05), peaked at 10min (þ100%, P< 0.05)
and returned to baseline at 60min (Fig. 2a and b). ERK
enzymatic activitywas also enhancedbyAng II (þ117%vs.
controls after 10min, P< 0.05) (Fig. 2c). The rises in both
ERK phosphorylation and enzymatic activity were abol-
ished by AT1 antagonism (Fig. 2a and c), whereas AT2
inhibition did not affect the ERK response to Ang IIrized reproduction of this article is prohibited.
. Representative western blots of phosphorylated (p-ERK) and total ERK
shown. ERK activation in NF is abolished by AT1 antagonism. (b) Time
iling (NF, n¼6) and failing myocytes (ICM, n¼14; DCM, n¼19). (c)
K1/2 activity in Ang II-stimulated myocytes in nonfailing (NF, n¼6) and
ilated cardiomyopathy; ERK, extracellular signal-regulated kinase; ICM,
lar signal-regulated kinase. P<0.05 vs. unstimulated myocytes;
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Fig. 3
JNK activity in Ang II-stimulated (100 nmol/l) myocytes. (a) Time course
of JNK activity assayed by phosphorylation of c-Jun. Representative
western blot from nonfailing (NF) myocytes is shown. (b)
Representative western blots showing the effects of AT1 (valsartan)
and AT2 (PD123319) selective antagonists on nonfailing and failing
(ICM and DCM) myocytes. (c) Bar graph shows the effects of AT1
(valsartan) and AT2 (PD123319) selective antagonists on JNK activity
in Ang II-stimulated nonfailing (NF, n¼6) and failing myocytes (ICM,
n¼14; DCM, n¼19). Ang II, angiotensin II; DCM, dilated
cardiomyopathy; ICM, ischemic cardiomyopathy; JNK, c-Jun N-terminal
kinase; NF, nonfailing. P<0.05 vs. unstimulated myocytes.(Fig. 2c). Conversely, Ang II stimulation failed to
increase ERK phosphorylation at all experimental times
in the failing myocytes from both DCM and ICM hearts
(Fig. 2a and b). The ERK enzymatic activity of the failing
myocytes only marginally increased in response to Ang II
stimulation (þ31% after 10min, P< 0.05) (Fig. 2c).
JNK activity in nonfailing myocytes was increased by
Ang II stimulation in as little as 10min (þ160% vs.
baseline, P< 0.05); it peaked at 20min (175%, P< 0.05)
and returned to baseline after 60min (Fig. 3a). The
enhancement in JNK activity was abolished by the AT1
antagonist (Fig. 3b and c). In contrast with the ERK
pattern, JNK activity increased following Ang II stimu-
lation in bothDCM(þ189%,P< 0.05) and ICMmyocytes
(þ142%, P< 0.05) (Fig. 3b and c).opyright © Lippincott Williams & Wilkins. UnauthAng II stimulation resulted in increasedmyocyte levels of
MKP1 (60min), MKP2 (60min), and MKP3 (30–60min)
only in nonfailing myocytes (Fig. 4). Western blot
analysis revealed higher levels of MKP1, MKP2, and
MKP3 in failing myocytes than in nonfailing unstimu-
lated ones (Fig. 4).
Discussion
The present study reveals for the first time an altered
myocyte intracellular response to Ang II in heart failure
independent from changes in membrane receptors. The
impaired Ang II-induced IGF-I and ET-1 release by
human failing ventricular myocytes is associated with
an impaired Ang II–ERK signaling.
Angiotensin II–extracellular signal-regulated kinase
signaling mediates insulin-like growth factor-I and
endothelin-1 release
Differently from what has been observed in other
species, Ang II does not acutely enhance contractility
of human and rat left ventricular myocytes [22–25]. In
addition, Ang II 10–11 to 10–7mol/l failed to elicit Ca2þ
influx responses in adult rat ventricular cardiomyocytes
[26]. However, when incubation time was prolonged
(>15min), Ang II induced a concentration-dependent
increase in rat myocyte contractility, an effect completely
blocked by ET-1 antagonists [15,27]. Likewise, the pro-
gressive increases in force and in Caþ transients occurring
over 15min in stretched papillary muscles were blocked
by both AT1 and endothelin receptor antagonists [28].
In-vivo studies in pig heart showed that the early release
of Ang II stored in the cardiomyocyte cytoplasm granules
[3] was followed by an increase in the mRNA of pre-
proET-1 and angiotensinogen with final ET-1 release
and recovery of cardiac contractility [2]. ET-1 gene
expression and peptide release, as well as the recovery
of contractility, were all abrogated by AT1 receptor
blockade [3]. Therefore, the participation of growth
factors in mediating the inotropic effect of Ang II was
demonstrated in ventricular myocytes, multicellular
preparations and in in-vivo studies. It is now considered
that Ang II-induced release of ET-1 activates the
Naþ/Hþ exchanger in an autocrine/paracrine fashion
promoting the influx of Ca2þ [27] and intracellular alka-
linization, which further improves the responsiveness of
myofilaments to calcium [29]. These changes finally
result in increased contractility [30]. However, the
relative role of the different intracellular pathways acti-
vated by Ang II in causing ET-1 release by human
myocytes remains to be defined.
According to the present findings, ERK antagonism com-
pletely abolishedET-1 and IGF-Ipeptide release, extend-
ingpreviousobservationsobtainedinneonatalratmyocytes
to adult human cells [31]. Conversely, JNK inhibition
caused only a minor reduction in ET-1 release with no
effects on IGF-I release. In addition, the lack of increase inorized reproduction of this article is prohibited.
C2036 Journal of Hypertension 2008, Vol 26 No 10
Fig. 4
Effects of Ang II (100 nmol/l) stimulation on the expression of MKP1, MKP2, and MKP3 in myocytes isolated from nonfailing (NF, left) and DCM
(right) hearts. Upper panels: representative western blots. Lower graphs: mean levels of MKP in NF (empty bars) and DCM myocytes (filled bars) at
different times. Values are expressed as percentage vs. baseline values in unstimulated cells. DCM, dilated cardiomyopathy; MKP, mitogen-activated
protein kinase phosphatases. P<0.05 vs. baseline values.ET-1 and IGF release following JNK inhibition excludes a
possible inhibitory effect of JNK on growth factor release.
In conclusion, these experiments confirm the redundant
role of JNK inET-1 release [32,33] that is conceivablewith
the effect of JNK downstream from ERK [34].
Altered angiotensin II–extracellular signal-regulated
kinase activation in failing myocytes
Evidence obtained in humans suggests that this mech-
anism may be altered in the progression to failure. The
reduction in cardiac contractility characterizing the tran-
sition from hypertrophy to failure in patients with aortic
valve disease was indeed found to be associated with
reduced cardiac production of IGF-I and ET-1 [4], not-
withstanding the progressive increase in Ang II cardiac
generation. In patients with heart failure, the progressive
reduction in contractility, marked by the increase in left
ventricular stress, was finally associated with reducedopyright © Lippincott Williams & Wilkins. Unauthocardiac production of growth factors (IGF-I and ET-1)
and progressive increase in Ang II cardiac generation [5].
In failing hearts, a reduced myocyte expression of ET-1
and IGF-I genes was observed by in-situ hybridization,
and the capability of Ang II to induce ET-1 and IGF-I
gene activation and peptide release was finally lost in
ventricular myocytes isolated from end-stage failing
hearts [5].
The present results reveal, for the first time, that this
pattern of response is associated with a blunted ERK
activation and a preserved JNK response to Ang II
stimulation. No significant differences were found
between DCM and ICM myocytes, thus indicating that
ERK impairment is inherent in heart failure.
ERK is now considered to be a protective signaling
pathway [9,10], its deletion predisposing the heart torized reproduction of this article is prohibited.
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and ET-1 [14] regulate myocyte survival, so that the
altered myocyte response to Ang II might favor the
progression to failure. In our nonfailing myocytes, the
MKP activation occurring at 30–60min closely corre-
sponds to ERK and JNK dephosphorylation. MKP1,
MKP2, and MKP3 have been found to be increased in
human failing hearts [7] and according to the present data
are also increased in failing myocytes. The relative
excess of phosphatases might thus contribute to ERK
impairment in human failing myocytes. However, the
lack of differences between the pattern of the three
MKP investigated, as well as the normalcy of Ang II–
JNK activation in failing myocytes, does not support a
primary role for the altered MKP pattern in determining
the ERK impairment.
The observed reduced ERK response to Ang II might
also attract interest in possible alterations in Ang
II-induced Ca mobilization in failing myocytes, an aspect
indeed not covered by our experiments. Unlike JNK, the
ERK1/2 response to Ang II was indeed reported to be
influenced by the release of calcium from inositol 1,4,5-
trisphosphate (IP3)-sensitive intracellular stores (sarco-
plasmic reticulum) both in vascular smooth muscle cells
[35,36] and in cardiomyocytes isolated from neonatal rats
[37]. However, although a reduced calcium release from
intracellular stores was consistently observed in human
failing ventricular myocytes [38–41], we did not specifi-
cally investigate Ca mobilization in our study, so the
possible participation of this mechanism can only be
hypothesized. Therefore, these experiments, although
not clarifying in detail the mechanisms involved in the
reduced ERK response in failing myocytes, provide
evidence in support of a direct link between the impair-
ment of an important intracellular pathway and reduced
growth factor formation in human failing myocytes.
The selective ERK impairment we observed in failing
cardiomyocytes differs from studies obtained in homogen-
ated human failing hearts, the latter giving conflicting
results. Samples obtained from patients with heart failure
either due to coronary artery disease or idiopathic dilated
cardiomyopathy revealed an increase in all three MAPKs
[42]. In comparison, levels of activated ERK were
unchanged in heart samples from patients with heart fail-
ure secondary to ischemic heart disease, whereas levels of
JNK and p38 MAPK activation were significantly
increased [6]. In patients with idiopathic dilated cardio-
myopathy, no increase inERKactivity in failing heartswas
reported [7], notwithstanding a three-fold increase in the
protein level for ERK. In the same study, JNK and p38
MAPK protein levels were not different in failing hearts
although the activity of both was decreased [7]. More
recently, reduced ERK activation was found in the hearts
of hypertensive patients who developed heart failure [43].
Different patterns of MAPK activation in homogenatedopyright © Lippincott Williams & Wilkins. Unauthheart were thus observed in patients with different causes
of the disease. Indeed, no true discrepancy may exist
because we investigated the pattern of response to Ang
II rather than the ‘status’ of thewholemyocardium and the
two aspects cannot be compared. The use of isolated
human ventricular myocytes certainly constitutes an
advance because the present findings suggest that, regard-
less of the cause of the disease, the impaired Ang II–ERK
signaling might play a causative role in the loss of Ang II
physiological activity on human failing myocytes.
Rather than indicating a total downregulation of Ang II
effects, the present findings support the existence of a
complex alteration in Ang II-mediated intracellular sig-
naling in failing cardiomyocytes. In other cell types, the
signaling cascade linking the activation of the nuclear
transcriptional changes and cell growth to Ang II type I
receptor stimulation was found to include the phos-
phorylation of JAK2, a soluble tyrosine kinase [44] also
involved in the transmission of the inflammatory processes
[45].Recentdata showed thatAng IIwas unable to activate
JAK2 in human nonfailing myocytes, whereas it did acti-
vate the same pathway in the failing myocytes [8]. The
enhanced ROS generation appeared to be the essential
factor for JAK2 activation in the failing myocytes [8].
AlthoughAng II-mediatedROSgenerationwas also found
to be involved in JNK activation with no effect on ERK1/2
[46], we did not extensively investigate the role of ROS in
the preserved JNK response due to the limited availability
of human myocytes. In conclusion, the complex of these
data clearly indicates the occurrence of a derangement of
Ang II signaling in failing cardiomyocytes, supporting the
use of Ang II antagonism in this clinical setting.
Study limitations
The possibility that we isolated a selected group of
myocytes cannot be excluded although a similar unin-
tentional selection has to be hypothesized also in con-
trols. However, the selected population, although ‘robust’
enough to survive the stress of isolation, shows different
characteristics when compared with adult nonfailing
myocytes. Therefore, although present results cannot
be extended to the organ level, they identify important
functional aspect of active cardiac cells, that is, the
capability of myocytes to react to the enhanced Ang II
production in heart failure [5].
Ang II-mediated signal transduction to AT1 receptors
may result from the effects of Ang II on contaminating
fibroblasts. A high prevalence of contaminating fibro-
blasts (>10%) has been reported when neonatal rat
cardiac cells are isolated and cultured [47]. Although
the possibility that myocyte samples may be contami-
nated by other cell types cannot be excluded in any
study investigating isolated myocytes, our studies were
performed with the use of adult cells, and our cell
suspensions were preplated to reduce the number oforized reproduction of this article is prohibited.
C2038 Journal of Hypertension 2008, Vol 26 No 10contaminating fibroblasts because, unlike myocytes iso-
lated from neonatal rats, adult myocytes do not attach to
culture plates. In addition, we used freshly isolated cells
to avoid the progressive increase in the prevalence of
contaminating fibroblasts with culture [48]. Finally, cell
suspensions obtained in the three groups did not signifi-
cantly differ with regard to the number of nonmyocyte
cells identified by their appearance under phase contrast
microscopy and by immunocytochemical staining.
Failing myocytes were obtained from patients receiving
a variety of drugs, including AT1 antagonists. A
possible interference of retained AT1 antagonists with
Ang II–ERK activation can be excluded because the
Ang II–JNK signaling was unchanged in the same
human failing myocytes.
Conclusion
The present findings reveal, for the first time, an import-
ant derangement of Ang II signaling in human failing
ventricular cardiomyocytes with a severe impairment of
the ERK pathway. Although the present cross-sectional
study does not allow the role of ERK impairment in the
single patient to be defined clearly, the altered myocyte
response might favor the progression to failure.
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